

Margarida Juliã - Sapã©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3983849/publications.pdf>

Version: 2024-02-01

66
papers

1,882
citations

331538

21
h-index

265120

42
g-index

69
all docs

69
docs citations

69
times ranked

1619
citing authors

#	ARTICLE	IF	CITATIONS
1	Extraction of artefactual MRS patterns from a large database using non-negative matrix factorization. NMR in Biomedicine, 2022, 35, e4193.	1.6	6
2	Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images. NMR in Biomedicine, 2020, 33, e4229.	1.6	15
3	Unraveling response to temozolomide in preclinical GL261 glioblastoma with MRI/MRSI using radiomics and signal source extraction. Scientific Reports, 2020, 10, 19699.	1.6	7
4	Interpreting response to TMZ therapy in murine GL261 glioblastoma by combining Radiomics, Convex-NMF and feature selection in MRI/MRSI data analysis. , 2020, , .		0
5	Robust Conditional Independence maps of single-voxel Magnetic Resonance Spectra to elucidate associations between brain tumours and metabolites. PLoS ONE, 2020, 15, e0235057.	1.1	2
6	Embedding MRI information into MRSI data source extraction improves brain tumour delineation in animal models. PLoS ONE, 2019, 14, e0220809.	1.1	3
7	Cancer metabolism in a snapshot: MRS(I). NMR in Biomedicine, 2019, 32, e4054.	1.6	17
8	Quality of clinical brain tumor MR spectra judged by humans and machine learning tools. Magnetic Resonance in Medicine, 2018, 79, 2500-2510.	1.9	18
9	Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide. NMR in Biomedicine, 2017, 30, e3748.	1.6	23
10	Brain metabolic pattern analysis using a magnetic resonance spectra classification software in experimental stroke. BMC Neuroscience, 2017, 18, 13.	0.8	5
11	Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment. Metabolites, 2017, 7, 20.	1.3	19
12	MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis. NMR in Biomedicine, 2016, 29, 732-743.	1.6	19
13	Automated Quality Control for Proton Magnetic Resonance Spectroscopy Data Using Convex Non-negative Matrix Factorization. Lecture Notes in Computer Science, 2016, , 719-727.	1.0	4
14	From raw data to data-analysis for magnetic resonance spectroscopy – the missing link: jMRUI2XML. BMC Bioinformatics, 2015, 16, 378.	1.2	9
15	Classification of brain tumours from MR spectra: the INTERPRET collaboration and its outcomes. NMR in Biomedicine, 2015, 28, 1772-1787.	1.6	19
16	Robustness of Equations that Define Molecular Subtypes of Glioblastoma Tumors Based on Five Transcripts Measured by RT-PCR. OMICS A Journal of Integrative Biology, 2015, 19, 41-51.	1.0	2
17	Non-invasive grading of astrocytic tumours from the relative contents of myo-inositol and glycine measured by in vivo mrs. Journal of the Belgian Society of Radiology, 2015, 94, 319.	0.2	17
18	Usefulness of Proton Magnetic Resonance Spectroscopy in the Clinical Management of Brain Tumors. , 2014, , 141-161.		0

#	ARTICLE	IF	CITATIONS
19	Semi-supervised source extraction methodology for the nosological imaging of glioblastoma response to therapy. , 2014, , .		2
20	Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma. NMR in Biomedicine, 2014, 27, 1333-1345.	1.6	21
21	Automatic relevance source determination in human brain tumors using Bayesian NMF. , 2014, , .		1
22	Multicentre evaluation of the INTERPRET decision support system 2.0 for brain tumour classification. NMR in Biomedicine, 2014, 27, 1009-1018.	1.6	10
23	A Novel Semi-Supervised Methodology for Extracting Tumor Type-Specific MRS Sources in Human Brain Data. PLoS ONE, 2013, 8, e83773.	1.1	18
24	Strategies for annotation and curation of translational databases: the eTUMOUR project. Database: the Journal of Biological Databases and Curation, 2012, 2012, bas035-bas035.	1.4	17
25	Development of robust discriminant equations for assessing subtypes of glioblastoma biopsies. British Journal of Cancer, 2012, 106, 1816-1825.	2.9	8
26	Improving the classification of brain tumors in mice with perturbation enhanced (PE)-MRSI. Integrative Biology (United Kingdom), 2012, 4, 183-191.	0.6	17
27	Non-negative matrix factorisation methods for the spectral decomposition of MRS data from human brain tumours. BMC Bioinformatics, 2012, 13, 38.	1.2	28
28	In Vivo Magnetic Resonance Spectroscopic Imaging and Ex Vivo Quantitative Neuropathology by High Resolution Magic Angle Spinning Proton Magnetic Resonance Spectroscopy. Neuromethods, 2012, , 329-365.	0.2	3
29	Convex Non-Negative Matrix Factorization for Brain Tumor Delimitation from MRSI Data. PLoS ONE, 2012, 7, e47824.	1.1	39
30	Prospective diagnostic performance evaluation of single-voxel ¹ H MRS for typing and grading of brain tumours. NMR in Biomedicine, 2012, 25, 661-673.	1.6	55
31	Robust discrimination of glioblastomas from metastatic brain tumors on the basis of single-voxel ¹ H MRS. NMR in Biomedicine, 2012, 25, 819-828.	1.6	27
32	Brain Tumor Pathological Area Delimitation through Non-negative Matrix Factorization. , 2011, , .		0
33	Proton MR Spectroscopy Provides Relevant Prognostic Information in High-Grade Astrocytomas. American Journal of Neuroradiology, 2011, 32, 74-80.	1.2	33
34	Incremental Gaussian Discriminant Analysis based on Graybill and Deal weighted combination of estimators for brain tumour diagnosis. Journal of Biomedical Informatics, 2011, 44, 677-687.	2.5	14
35	Compatibility between 3T ¹ H SV-MRS data and automatic brain tumour diagnosis support systems based on databases of 1.5T ¹ H SV-MRS spectra. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2011, 24, 35-42.	1.1	18
36	On the relevance of automatically selected single-voxel MRS and multimodal MRI and MRSI features for brain tumour differentiation. Computers in Biology and Medicine, 2011, 41, 87-97.	3.9	60

#	ARTICLE	IF	CITATIONS
37	Spectral decomposition methods for the analysis of MRS information from human brain tumors. , 2011, , .		4
38	Diagnosis and Staging of Brain Tumours: Magnetic Resonance Single Voxel Spectra. , 2011, , 227-243.		1
39	Improving the classification of brain tumors in mice with perturbation enhanced (PE)-MRSI. BMC Proceedings, 2010, 4, .	1.8	0
40	Feature and model selection with discriminatory visualization for diagnostic classification of brain tumors. Neurocomputing, 2010, 73, 622-632.	3.5	38
41	SpectraClassifier 1.0: a user friendly, automated MRS-based classifier-development system. BMC Bioinformatics, 2010, 11, 106.	1.2	31
42	The INTERPRET Decision-Support System version 3.0 for evaluation of Magnetic Resonance Spectroscopy data from human brain tumours and other abnormal brain masses. BMC Bioinformatics, 2010, 11, 581.	1.2	43
43	Development of a Predictor for Human Brain Tumors Based on Gene Expression Values Obtained from Two Types of Microarray Technologies. OMICS A Journal of Integrative Biology, 2010, 14, 157-164.	1.0	12
44	Proton MR Spectroscopy Improves Discrimination between Tumor and Pseudotumoral Lesion in Solid Brain Masses. American Journal of Neuroradiology, 2009, 30, 544-551.	1.2	92
45	Outlier exploration and diagnostic classification of a multi-centre 1H-MRS brain tumour database. Neurocomputing, 2009, 72, 3085-3097.	3.5	24
46	Multiprojectâ€“multicenter evaluation of automatic brain tumor classification by magnetic resonance spectroscopy. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2009, 22, 5-18.	1.1	126
47	HealthAgents: distributed multi-agent brain tumor diagnosis andÂˆprognosis. Applied Intelligence, 2009, 30, 191-202.	3.3	78
48	Ranking of Brain Tumour Classifiers Using a Bayesian Approach. Lecture Notes in Computer Science, 2009, , 1005-1012.	1.0	2
49	MRS quality assessment in a multicentre study on MRS-based classification of brain tumours. NMR in Biomedicine, 2008, 21, 148-158.	1.6	43
50	The effect of combining two echo times in automatic brain tumor classification by MRS. NMR in Biomedicine, 2008, 21, 1112-1125.	1.6	44
51	MRS in clinical practice. Application to brain tumour MRS. , 2008, , .		1
52	Classification, Dimensionality Reduction, and Maximally Discriminatory Visualization of a Multicentre 1H-MRS Database of Brain Tumors. , 2008, , .		3
53	Rule-Based Assistance to Brain Tumour Diagnosis Using LR-FIR. Lecture Notes in Computer Science, 2008, , 173-180.	1.0	5
54	Exploratory Characterization of Outliers in a Multi-centre 1H-MRS Brain Tumour Dataset. Lecture Notes in Computer Science, 2008, , 189-196.	1.0	5

#	ARTICLE	IF	CITATIONS
55	Conceptual Graphs Based Information Retrieval in HealthAgents. Proceedings of the IEEE Symposium on Computer-Based Medical Systems, 2007, , .	0.0	6
56	Genomics and Metabolomics Research for Brain Tumour Diagnosis Based on Machine Learning. Lecture Notes in Computer Science, 2007, , 1012-1019.	1.0	3
57	On the Implementation of HealthAgents: Agent-Based Brain Tumour Diagnosis. , 2007, , 5-24.		3
58	A Multi-Centre, Web-Accessible and Quality Control-Checked Database of in vivo MR Spectra of Brain Tumour Patients. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2006, 19, 22-33.	1.1	78
59	Development of a decision support system for diagnosis and grading of brain tumours using in vivo magnetic resonance single voxel spectra. NMR in Biomedicine, 2006, 19, 411-434.	1.6	216
60	Comparison between neuroimaging classifications and histopathological diagnoses using an international multicenter brain tumor magnetic resonance imaging database. Journal of Neurosurgery, 2006, 105, 6-14.	0.9	126
61	Brain tumor classification by proton MR spectroscopy: comparison of diagnostic accuracy at short and long TE. American Journal of Neuroradiology, 2004, 25, 1696-704.	1.2	135
62	Protective Effect of HOE642, a Selective Blocker of Na ⁺ -H ⁺ Exchange, Against the Development of Rigor Contracture in Rat Ventricular Myocytes. Experimental Physiology, 2000, 85, 17-25.	0.9	8
63	LDL and Lp(a) oxidation: Protective role of HDL. Atherosclerosis, 1999, 144, 46.	0.4	0
64	Gap Junction Uncoupler Heptanol Prevents Cell-to-Cell Progression of Hypercontracture and Limits Necrosis During Myocardial Reperfusion. Circulation, 1997, 96, 3579-3586.	1.6	172
65	Pre-treatment with trimetazidine increases sarcolemmal mechanical resistance in reoxygenated myocytes. Cardiovascular Research, 1996, 32, 587-592.	1.8	20
66	Pre-treatment with trimetazidine increases sarcolemmal mechanical resistance in reoxygenated myocytes. Cardiovascular Research, 1996, 32, 587-592.	1.8	2